Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid a randomized controlled trial

JAMA

Volumn 275, Issue 18, 1996, Pages 1428-1431

  Feldman, Mark ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BICARBONATE; CALCIUM CARBONATE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; TUMS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH ACID SECRETION; STOMACH PH;

EID: 0029979066     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.18.1428     Document Type: Article

References (16)

1. The Gallup Organization: Gallup Survey on Heartburn, Across America. Lincoln, Neb: Gallup Organization; 1988.
2. Barnett CC, Richardson CT. In vivo and in vitro evaluation of magnesium-aluminum hydroxide antacid tablets and liquid. Dig Dis Sci. 1985;30:1049-1052.
3. Kirsner JB. A further study of the effects of various antacids on the hydrogen-ion concentration of the gastric contents. Am J Dig Dis. 1941;8:53-56.
4. Fordtran JS, Collyns JAH. Antacid pharmacology in duodenal ulcer: effect of antacids on postcibal gastric acidity and peptic activity. N Engl J Med. 1966;274:921-927.
5. Fordtran JS. Acid rebound. N Engl J Med. 1968;279:900-905.
6. Fordtran JS, Morawski SG, Richardson CT. In vivo and in vitro evaluation of liquid antacids. N Engl J Med. 1973;288:923-928.
7. 2-receptor antagonists. Arch Intern Med. 1993;153:415-2424.
8. Goldschmiedt M, Feldman M. Gastric secretion in health and disease. In: Sleisenger MH, Fordtran JS, eds. Textbook of Gastrointestinal Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 1993:524-544.
9. Physicians' Desk Reference for Nonprescription Drugs. 16th ed. Montvale, NJ: Medical Economics Data Production Co; 1995.
10. Fordtran JS, Walsh JH. Gastric acid secretion rate and buffer content of the stomach after eating: results in normal subjects and in patients with duodenal ulcer. J Clin Invest. 1973;52:645-657.
11. 2-receptor antagonist (famotidine). Am J Ther. 1995;2:304-313.
12. 2-receptor antagonists: standard therapy for acid-peptic diseases. N Engl J Med. 1990;323:1672-1680.
13. Maton PN. Omeprazole. N Engl J Med. 1991;324:965-975.
14. Lansoprazole. Med Lett. 1995;37:63-66.
15. Laskin OL, Patterson PM, Shingo S, Lasseter KC, Shamblen EC. Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trial. J Clin Pharmacol. 1993;33:636-639.
16. Barzaghi N, Gatti G, Crema F, Perucca E. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29:670-672.